

**INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-T
LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LE
PROGNOSTIC FACTORS**

Hematological Oncology

35, 109-111

DOI: [10.1002/hon.2437_99](https://doi.org/10.1002/hon.2437_99)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. <i>Blood</i> , 2018, 131, 1910-1919. | 0.6 | 339 |
| 2 | Chronic lymphocytic leukemia is becoming more complex: how to define complex karyotype?. <i>Leukemia and Lymphoma</i> , 2018, 59, 521-522. | 0.6 | 3 |
| 3 | High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. <i>Blood</i> , 2018, 132, 892-902. | 0.6 | 83 |
| 4 | Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410. | 2.0 | 24 |
| 5 | Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363. | 2.0 | 305 |
| 6 | Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 487-498. | 1.8 | 9 |
| 7 | Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 302-309. | 1.2 | 11 |
| 8 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 43-56. | 5.1 | 448 |
| 9 | Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 174-183.e3. | 0.2 | 21 |
| 10 | Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. <i>Nature Communications</i> , 2020, 11, 577. | 5.8 | 69 |